Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 118Other hematologic neoplasm 48Genitourinary 35Sarcoma 4Plasma cell 4Gynecologic 4Gastrointestinal 4Breast 4Thoracic 2Tumor-Agnostic 1Dermatologic 1CNS 1

Conditions

Multiple Myeloma 4Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 871Bortezomib 457Lenalidomide 456Cyclophosphamide 365Melphalan 272Calcium Dobesilate 263daratumumab 234pomalidomide 208carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74isatuximab 69Cyclosporine 68auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 57Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Prednisolone × Plasma cell × Clear all
NCT01539083 2025-02-04

VCAT

Janssen Scientific Affairs, LLC

Phase 3 Completed
256 enrolled 13 charts
Plasma cell

Multiple Myeloma

NCT00985959 2013-12-02

A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)

Janssen Pharmaceutical K.K.

Phase 1 Completed
101 enrolled 15 charts
Plasma cell

Multiple Myeloma

NCT00003603 2013-09-20

Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Unknown
660 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01179490 2013-03-18

Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma

SymBio Pharmaceuticals

Phase 2 Terminated
5 enrolled 30 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡